From cereal and granola to snacks and soda, Big Chalk’s Fall 2025 report outlines where GLP-1 users are cutting back - and ...
Based Probiotic Category Ahead of 2026 Weight-Loss Season - Ingredient Research, Regulatory Context, and Evidence Gaps ...
Drugmaker Eli Lilly said Thursday that an experimental pill form of popular GLP-1 medications helped people with type 2 diabetes lose an average of nearly 8% of their body weight after 40 weeks and ...
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) like semaglutide and liraglutide mimic endogenous incretin signals to stimulate glucose-dependent insulin release, thereby suppressing glucagon, ...
GLP-1s are used for type 2 diabetes, as well as weight loss in people with obesity or overweight with a related health condition. Read on for everything you need to know about GLP-1s for weight loss, ...
Brooke Boyarsky Pratt, CEO, and Dr. Angela Fitch, chief medical officer, are both co-founders of knownwell. More than 12% of U.S. adults now take a GLP-1 medication, marking one of the ...
Diabetes and obesity have become pressing health issues worldwide. Glucagon-like peptide-1 (GLP-1) receptor agonists, a class of medications widely used in the treatment of type 2 diabetes (T2D), have ...
From shifting grocery habits to new product opportunities, Circana’s insights reveal how brands and retailers can adapt to ...
The use of drugs like Ozempic, Wegovy and Zepbound in people with type 1 diabetes has risen sharply over the past decade, a new study finds, even though there’s little information on the drugs’ safety ...
GLP-1 weight loss drugs have taken the food industry by storm. The drugs, which reduce “food noise”, the desire to eat, and increase feelings of fullness, are seen by some as an existential risk to ...
More people are paying out-of-pocket for GLP-1 weight loss drugs — and more retailers are offering discounts on Zepbound, Ozempic, and Wegovy. Walmart will offer in-store pickup for Zepbound at ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results